AXSM - Axsome in licensing pact with Pharmanovia for sleep disorder therapy Sunosi
- Axsome Therapeutics ( NASDAQ: AXSM ) announced a licensing agreement with U.K.-based Pharmanovia on Wednesday for Sunosi, a medication indicated in Europe for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA).
- Per the terms, Pharmanovia will take over the commercialization and development rights for Sunosi in Europe and certain countries in the Middle East and North Africa (MENA).
- In return, Axsome ( AXSM ) will receive a $66M upfront payment in addition to sales-based and other milestones worth up to $101M. The company’s entitlement for royalty stands at a percentage of mid-twenties on net sales.
- Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor, was added to Axsome’s ( AXSM ) portfolio following an agreement with Jazz Pharmaceuticals ( JAZZ ) in March 2022.
For further details see:
Axsome in licensing pact with Pharmanovia for sleep disorder therapy Sunosi